_version_ 1784582134518775808
author Dinicola, Simona
Unfer, Vittorio
Facchinetti, Fabio
Soulage, Christophe O.
Greene, Nicholas D.
Bizzarri, Mariano
Laganà, Antonio Simone
Chan, Shiao-Yng
Bevilacqua, Arturo
Pkhaladze, Lali
Benvenga, Salvatore
Stringaro, Annarita
Barbaro, Daniele
Appetecchia, Marialuisa
Aragona, Cesare
Bezerra Espinola, Maria Salomè
Cantelmi, Tonino
Cavalli, Pietro
Chiu, Tony T.
Copp, Andrew J.
D’Anna, Rosario
Dewailly, Didier
Di Lorenzo, Cherubino
Diamanti-Kandarakis, Evanthia
Hernández Marín, Imelda
Hod, Moshe
Kamenov, Zdravko
Kandaraki, Eleni
Monastra, Giovanni
Montanino Oliva, Mario
Nestler, John E.
Nordio, Maurizio
Ozay, Ali C.
Papalou, Olga
Porcaro, Giuseppina
Prapas, Nikos
Roseff, Scott
Vazquez-Levin, Monica
Vucenik, Ivana
Wdowiak, Artur
author_facet Dinicola, Simona
Unfer, Vittorio
Facchinetti, Fabio
Soulage, Christophe O.
Greene, Nicholas D.
Bizzarri, Mariano
Laganà, Antonio Simone
Chan, Shiao-Yng
Bevilacqua, Arturo
Pkhaladze, Lali
Benvenga, Salvatore
Stringaro, Annarita
Barbaro, Daniele
Appetecchia, Marialuisa
Aragona, Cesare
Bezerra Espinola, Maria Salomè
Cantelmi, Tonino
Cavalli, Pietro
Chiu, Tony T.
Copp, Andrew J.
D’Anna, Rosario
Dewailly, Didier
Di Lorenzo, Cherubino
Diamanti-Kandarakis, Evanthia
Hernández Marín, Imelda
Hod, Moshe
Kamenov, Zdravko
Kandaraki, Eleni
Monastra, Giovanni
Montanino Oliva, Mario
Nestler, John E.
Nordio, Maurizio
Ozay, Ali C.
Papalou, Olga
Porcaro, Giuseppina
Prapas, Nikos
Roseff, Scott
Vazquez-Levin, Monica
Vucenik, Ivana
Wdowiak, Artur
author_sort Dinicola, Simona
collection PubMed
description Myo-inositol (myo-Ins) and D-chiro-inositol (D-chiro-Ins) are natural compounds involved in many biological pathways. Since the discovery of their involvement in endocrine signal transduction, myo-Ins and D-chiro-Ins supplementation has contributed to clinical approaches in ameliorating many gynecological and endocrinological diseases. Currently both myo-Ins and D-chiro-Ins are well-tolerated, effective alternative candidates to the classical insulin sensitizers, and are useful treatments in preventing and treating metabolic and reproductive disorders such as polycystic ovary syndrome (PCOS), gestational diabetes mellitus (GDM), and male fertility disturbances, like sperm abnormalities. Moreover, besides metabolic activity, myo-Ins and D-chiro-Ins deeply influence steroidogenesis, regulating the pools of androgens and estrogens, likely in opposite ways. Given the complexity of inositol-related mechanisms of action, many of their beneficial effects are still under scrutiny. Therefore, continuing research aims to discover new emerging roles and mechanisms that can allow clinicians to tailor inositol therapy and to use it in other medical areas, hitherto unexplored. The present paper outlines the established evidence on inositols and updates on recent research, namely concerning D-chiro-Ins involvement into steroidogenesis. In particular, D-chiro-Ins mediates insulin-induced testosterone biosynthesis from ovarian thecal cells and directly affects synthesis of estrogens by modulating the expression of the aromatase enzyme. Ovaries, as well as other organs and tissues, are characterized by a specific ratio of myo-Ins to D-chiro-Ins, which ensures their healthy state and proper functionality. Altered inositol ratios may account for pathological conditions, causing an imbalance in sex hormones. Such situations usually occur in association with medical conditions, such as PCOS, or as a consequence of some pharmacological treatments. Based on the physiological role of inositols and the pathological implications of altered myo-Ins to D-chiro-Ins ratios, inositol therapy may be designed with two different aims: (1) restoring the inositol physiological ratio; (2) altering the ratio in a controlled way to achieve specific effects.
format Online
Article
Text
id pubmed-8508595
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-85085952021-10-13 Inositols: From Established Knowledge to Novel Approaches Dinicola, Simona Unfer, Vittorio Facchinetti, Fabio Soulage, Christophe O. Greene, Nicholas D. Bizzarri, Mariano Laganà, Antonio Simone Chan, Shiao-Yng Bevilacqua, Arturo Pkhaladze, Lali Benvenga, Salvatore Stringaro, Annarita Barbaro, Daniele Appetecchia, Marialuisa Aragona, Cesare Bezerra Espinola, Maria Salomè Cantelmi, Tonino Cavalli, Pietro Chiu, Tony T. Copp, Andrew J. D’Anna, Rosario Dewailly, Didier Di Lorenzo, Cherubino Diamanti-Kandarakis, Evanthia Hernández Marín, Imelda Hod, Moshe Kamenov, Zdravko Kandaraki, Eleni Monastra, Giovanni Montanino Oliva, Mario Nestler, John E. Nordio, Maurizio Ozay, Ali C. Papalou, Olga Porcaro, Giuseppina Prapas, Nikos Roseff, Scott Vazquez-Levin, Monica Vucenik, Ivana Wdowiak, Artur Int J Mol Sci Review Myo-inositol (myo-Ins) and D-chiro-inositol (D-chiro-Ins) are natural compounds involved in many biological pathways. Since the discovery of their involvement in endocrine signal transduction, myo-Ins and D-chiro-Ins supplementation has contributed to clinical approaches in ameliorating many gynecological and endocrinological diseases. Currently both myo-Ins and D-chiro-Ins are well-tolerated, effective alternative candidates to the classical insulin sensitizers, and are useful treatments in preventing and treating metabolic and reproductive disorders such as polycystic ovary syndrome (PCOS), gestational diabetes mellitus (GDM), and male fertility disturbances, like sperm abnormalities. Moreover, besides metabolic activity, myo-Ins and D-chiro-Ins deeply influence steroidogenesis, regulating the pools of androgens and estrogens, likely in opposite ways. Given the complexity of inositol-related mechanisms of action, many of their beneficial effects are still under scrutiny. Therefore, continuing research aims to discover new emerging roles and mechanisms that can allow clinicians to tailor inositol therapy and to use it in other medical areas, hitherto unexplored. The present paper outlines the established evidence on inositols and updates on recent research, namely concerning D-chiro-Ins involvement into steroidogenesis. In particular, D-chiro-Ins mediates insulin-induced testosterone biosynthesis from ovarian thecal cells and directly affects synthesis of estrogens by modulating the expression of the aromatase enzyme. Ovaries, as well as other organs and tissues, are characterized by a specific ratio of myo-Ins to D-chiro-Ins, which ensures their healthy state and proper functionality. Altered inositol ratios may account for pathological conditions, causing an imbalance in sex hormones. Such situations usually occur in association with medical conditions, such as PCOS, or as a consequence of some pharmacological treatments. Based on the physiological role of inositols and the pathological implications of altered myo-Ins to D-chiro-Ins ratios, inositol therapy may be designed with two different aims: (1) restoring the inositol physiological ratio; (2) altering the ratio in a controlled way to achieve specific effects. MDPI 2021-09-30 /pmc/articles/PMC8508595/ /pubmed/34638926 http://dx.doi.org/10.3390/ijms221910575 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Dinicola, Simona
Unfer, Vittorio
Facchinetti, Fabio
Soulage, Christophe O.
Greene, Nicholas D.
Bizzarri, Mariano
Laganà, Antonio Simone
Chan, Shiao-Yng
Bevilacqua, Arturo
Pkhaladze, Lali
Benvenga, Salvatore
Stringaro, Annarita
Barbaro, Daniele
Appetecchia, Marialuisa
Aragona, Cesare
Bezerra Espinola, Maria Salomè
Cantelmi, Tonino
Cavalli, Pietro
Chiu, Tony T.
Copp, Andrew J.
D’Anna, Rosario
Dewailly, Didier
Di Lorenzo, Cherubino
Diamanti-Kandarakis, Evanthia
Hernández Marín, Imelda
Hod, Moshe
Kamenov, Zdravko
Kandaraki, Eleni
Monastra, Giovanni
Montanino Oliva, Mario
Nestler, John E.
Nordio, Maurizio
Ozay, Ali C.
Papalou, Olga
Porcaro, Giuseppina
Prapas, Nikos
Roseff, Scott
Vazquez-Levin, Monica
Vucenik, Ivana
Wdowiak, Artur
Inositols: From Established Knowledge to Novel Approaches
title Inositols: From Established Knowledge to Novel Approaches
title_full Inositols: From Established Knowledge to Novel Approaches
title_fullStr Inositols: From Established Knowledge to Novel Approaches
title_full_unstemmed Inositols: From Established Knowledge to Novel Approaches
title_short Inositols: From Established Knowledge to Novel Approaches
title_sort inositols: from established knowledge to novel approaches
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8508595/
https://www.ncbi.nlm.nih.gov/pubmed/34638926
http://dx.doi.org/10.3390/ijms221910575
work_keys_str_mv AT dinicolasimona inositolsfromestablishedknowledgetonovelapproaches
AT unfervittorio inositolsfromestablishedknowledgetonovelapproaches
AT facchinettifabio inositolsfromestablishedknowledgetonovelapproaches
AT soulagechristopheo inositolsfromestablishedknowledgetonovelapproaches
AT greenenicholasd inositolsfromestablishedknowledgetonovelapproaches
AT bizzarrimariano inositolsfromestablishedknowledgetonovelapproaches
AT laganaantoniosimone inositolsfromestablishedknowledgetonovelapproaches
AT chanshiaoyng inositolsfromestablishedknowledgetonovelapproaches
AT bevilacquaarturo inositolsfromestablishedknowledgetonovelapproaches
AT pkhaladzelali inositolsfromestablishedknowledgetonovelapproaches
AT benvengasalvatore inositolsfromestablishedknowledgetonovelapproaches
AT stringaroannarita inositolsfromestablishedknowledgetonovelapproaches
AT barbarodaniele inositolsfromestablishedknowledgetonovelapproaches
AT appetecchiamarialuisa inositolsfromestablishedknowledgetonovelapproaches
AT aragonacesare inositolsfromestablishedknowledgetonovelapproaches
AT bezerraespinolamariasalome inositolsfromestablishedknowledgetonovelapproaches
AT cantelmitonino inositolsfromestablishedknowledgetonovelapproaches
AT cavallipietro inositolsfromestablishedknowledgetonovelapproaches
AT chiutonyt inositolsfromestablishedknowledgetonovelapproaches
AT coppandrewj inositolsfromestablishedknowledgetonovelapproaches
AT dannarosario inositolsfromestablishedknowledgetonovelapproaches
AT dewaillydidier inositolsfromestablishedknowledgetonovelapproaches
AT dilorenzocherubino inositolsfromestablishedknowledgetonovelapproaches
AT diamantikandarakisevanthia inositolsfromestablishedknowledgetonovelapproaches
AT hernandezmarinimelda inositolsfromestablishedknowledgetonovelapproaches
AT hodmoshe inositolsfromestablishedknowledgetonovelapproaches
AT kamenovzdravko inositolsfromestablishedknowledgetonovelapproaches
AT kandarakieleni inositolsfromestablishedknowledgetonovelapproaches
AT monastragiovanni inositolsfromestablishedknowledgetonovelapproaches
AT montaninoolivamario inositolsfromestablishedknowledgetonovelapproaches
AT nestlerjohne inositolsfromestablishedknowledgetonovelapproaches
AT nordiomaurizio inositolsfromestablishedknowledgetonovelapproaches
AT ozayalic inositolsfromestablishedknowledgetonovelapproaches
AT papalouolga inositolsfromestablishedknowledgetonovelapproaches
AT porcarogiuseppina inositolsfromestablishedknowledgetonovelapproaches
AT prapasnikos inositolsfromestablishedknowledgetonovelapproaches
AT roseffscott inositolsfromestablishedknowledgetonovelapproaches
AT vazquezlevinmonica inositolsfromestablishedknowledgetonovelapproaches
AT vucenikivana inositolsfromestablishedknowledgetonovelapproaches
AT wdowiakartur inositolsfromestablishedknowledgetonovelapproaches